Portable dialysis machine maker Outset Medical posts $242M IPO

Outset's portable Tablo machine includes integrated water purification hardware, which allows it to run off of tap water and a basic electrical outlet. (Outset Medical)

After raising $125 million for its commercialization efforts earlier this year, portable dialysis machine manufacturer Outset Medical is now going public with a $241.7 million Nasdaq IPO.

Trading under the ticker symbol "OM," the company priced 8.95 million of its shares at $27 apiece, upsizing its previous plans to offer 7.6 million shares between $22 and $24—a 38% boost overall, according to Renaissance Capital. The offering is set to close Sept. 17.

The former Fierce 15 winner’s Tablo hemodialysis system is designed to serve as a standalone unit. While traditional machines may require a connection to an outside source of clean water, the Tablo unit includes integrated water purification hardware, allowing it to run off of tap water and a basic electrical outlet.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

It also employs prewired, single-use cartridges to reduce the number of steps and training required to set up the machine. The system can perform dialysis for as little as 30 minutes or as long as 24 hours.

RELATED: Outset Medical secures another $125M for its portable dialysis machine

In July, the company reported the system’s first use within a patient’s home, after it received an expanded clearance from the FDA in late March. 

“Tablo was designed to simplify dialysis, making it easier and more accessible for patients to take advantage of the safety, convenience and flexibility of dialyzing at home,” CEO Leslie Trigg said at the time. “We are proud to offer them this new, life-enhancing option, particularly in light of the COVID-19 related challenges dialysis patients and providers are experiencing.”

In May, the company deployed 50 Tablo systems for emergency use to five hospitals in New York City and Long Island under a multiyear contract with the U.S. Department of Health and Human Services, originally formed to provide dialysis services in communities following natural disasters.

Outset Medical estimates that dialysis therapy is currently delivered to more than 550,000 patients in the U.S. multiple times per week, totaling 85 million treatments per year and costing about $75 billion.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.